RESUMO
Decellularization is a novel technique employed for scaffold manufacturing, as a strategy for skeletal muscle (SM) tissue engineering applications. However, poor decellularization efficacy is still a problem for the use of decellularized scaffolds as truly biocompatible biomaterials. For recellularization, adipose-derived stem cells (ASCs) are a good option, due to their immunomodulatory and pro-regenerative capacity, but few studies have described their combination with muscle-decellularized matrices (mDMs). This work aimed to evaluate the efficiency of four multi-step decellularization protocols to produce mDMs and to investigate in vitro biocompatibility with ASCs. Here, we described the different efficacies of muscle decellularization methods, suggesting the need for stricter standardization of the method, considering the large range of applications in SM tissue engineering, which is also a promising platform for preclinical studies with rat disease models using autologous cells.
Assuntos
Tecido Adiposo , Músculo Esquelético , Engenharia Tecidual , Alicerces Teciduais , Engenharia Tecidual/métodos , Animais , Músculo Esquelético/citologia , Tecido Adiposo/citologia , Alicerces Teciduais/química , Ratos , Células-Tronco/citologia , Células-Tronco/metabolismo , Matriz Extracelular Descelularizada/química , Humanos , Células CultivadasRESUMO
The combination of magnetic hyperthermia therapy with the controlled release of chemotherapeutic agents in tumors may be an efficient therapeutic with few side effects because the bioavailability, tolerance and amount of the drug can be optimized. Here, we prepared magnetoliposomes consisting of magnetite nanoparticle cores and the anticancer drug gemcitabine encapsulated by a phospholipid bilayer. The potential of these magnetoliposomes for controlled drug release and cancer treatment via hyperthermic behavior was investigated. The magnetic nanoparticle encapsulation efficiency was dependent on the initial amount of magnetite nanoparticles present at the encapsulation stage; the best formulation was 66%. We chose this formulation to characterize the physicochemical properties of the magnetoliposomes and to encapsulate gemcitabine. The mean particle size and distribution were determined by dynamic light scattering (DLS), and the zeta potential was measured. The magnetoliposome formulations all had acceptable characteristics for systemic administration, with a mean size of approximately 150 nm and a polydispersity index <0.2. The magnetoliposomes were stable in aqueous suspension for at least one week, as determined by DLS. Temperature increases due to the dissipation energy of magnetoliposome suspensions subjected to an applied alternating magnetic field (AMF) were measured at different magnetic field intensities, and the values were appropriated for cancer treatments. The drug release profile at 37 °C showed that 17% of the gemcitabine was released after 72 h. Drug release from magnetoliposomes exposed to an AMF for 5 min reached 70%.
Assuntos
Antimetabólitos Antineoplásicos/farmacologia , Preparações de Ação Retardada/química , Desoxicitidina/análogos & derivados , Lipossomos/química , Nanopartículas de Magnetita/química , Animais , Antimetabólitos Antineoplásicos/metabolismo , Sobrevivência Celular/efeitos dos fármacos , Preparações de Ação Retardada/farmacologia , Desoxicitidina/metabolismo , Desoxicitidina/farmacologia , Composição de Medicamentos , Liberação Controlada de Fármacos , Estabilidade de Medicamentos , Óxido Ferroso-Férrico/química , Hipertermia Induzida/métodos , Luz , Lipossomos/farmacologia , Campos Magnéticos , Nanopartículas de Magnetita/ultraestrutura , Células-Tronco Mesenquimais/citologia , Células-Tronco Mesenquimais/efeitos dos fármacos , Tamanho da Partícula , Fotoquimioterapia/métodos , Cultura Primária de Células , Ratos , Ratos Endogâmicos Lew , GencitabinaRESUMO
The host immune system tends to reject xenogenic-implanted cells making tumor development in adult host animal models difficult. Immune system suppression is used for successful xenotransplantation of human cancer cells in many animal models. The studies of cancer development processes in vivo offer opportunities to understand cancer biology and discover new therapeutic strategies. In this context, zebrafish is a model that has been widely applied in the study of human diseases, such as cancer. However, the long-term immunosuppression of these adult zebrafish is still under study as a xenograft animal model for human cancer. This work aimed to evaluate the effects of 21 days of (long-term) exposure of dexamethasone in zebrafish-transplanted with MGSO-3 cells, human breast tumor cell line. Our results show that the animals, while kept on dexamethasone treatment, remained with a 50% reduction in the number of peripheral lymphocytes. In vitro data demonstrated that up to 7 days of dexamethasone treatment did not alter the morphology, proliferation, or viability of MGSO-3 cells. The animals that received a prolonged dexamethasone treatment allowed the engraftment of tumor cells in 100% of the zebrafish tested. These animals also showed tumor progression over 21 days. The experimental group that received only previous exposure to dexamethasone had their tumors regressed after 14 days. In conclusion, the prolonged use of dexamethasone in zebrafish showed a potential strategy for in vivo monitoring of xenograft tumor growth for development studies, as well as in anticancer drug discovery.
RESUMO
Arterial bypass graft implantation remains the primary therapy for patients with advanced cardiovascular disease, but most lack adequate saphenous vein or other conduits for bypass procedures and would benefit from a bioartificial conduit. This study aimed to produce human endothelial cells (hECs) in large scale, free from xenogeneic antigens, to develop a small diameter, compatible vessel for potential use as a vascular graft. Human adipose-derived stromal cells (hASCs) were isolated, cultured, and differentiated in the presence of human serum and used for the reendothelization of a decellularized rat aorta. hASC derived ECs (hASC-ECs) expressed VEGFR2, vWf and CD31 endothelial cell markers, the latter in higher levels than hASCs and HUVECs, and were shown to be functional. Decellularization protocol yielded aortas devoid of cell nuclei, with preserved structure, including a preserved basement membrane. When seeded with hASC-ECs, the decellularized aorta was completely reendothelized, and the hASC-ECs maintained their phenotype in this new condition. hASCs can be differentiated into functional hECs without the use of animal supplements and are capable of reendothelizing a decellularized rat aorta while maintaining their phenotype. The preservation of the basement membrane following decellularization supported the complete reendothelization of the scaffold with no cell migration towards other layers. This approach is potentially useful for rapid obtention of compatible, xenogeneic-free conduit.
Assuntos
Antígenos Heterófilos/biossíntese , Aorta/crescimento & desenvolvimento , Prótese Vascular , Células Endoteliais/metabolismo , Animais , Antígenos Heterófilos/imunologia , Aorta/metabolismo , Diferenciação Celular/genética , Movimento Celular/genética , Células Endoteliais/imunologia , Humanos , Ratos , Engenharia Tecidual , TransplantesRESUMO
Human orbital fat tissues are a potential source to isolate stem cells for the development of regenerative medicine therapies. For future safe clinical application of these cells, it is critical to establish animal component-free culture conditions as well as to clearly define the stem cell population characteristics differentiating them from other cell types, such as fibroblasts. Therefore, the present study aimed to compare phenotypic and functional characteristics of orbital fat-derived stem cells (OFSCs) and fibroblasts resident in the eyelid skin in donor-matched samples grown in culture medium supplemented with pooled allogeneic human serum (HS) replacing fetal bovine serum (FBS). We first investigated the proliferative effects of OFSCs on HS, and then we compared the alkaline phosphatase (AP) expression and activity, immunophenotypic profile, and in vitro multilineage differentiation potential of OFSCs side-by-side with fibroblasts. The results showed that HS enhanced OFSCs proliferation without compromising their immunophenotype, AP activity, and osteogenic, adipogenic, and chondrogenic differentiation capacities. In contrast to OFSCs, the fibroblasts did not exhibit AP expression and activity and did not have multilineage differentiation potential. The results enabled us to successfully distinguish OFSCs from fibroblasts populations, suggesting that AP expression/activity and multilineage differentiation assays can be used reliably to discriminate mesenchymal stem cells from fibroblasts. Our findings also support the feasibility of pooled allogeneic HS as a safer and more effective alternative to FBS for clinical applications.
Assuntos
Tecido Adiposo/citologia , Fosfatase Alcalina/metabolismo , Diferenciação Celular/efeitos dos fármacos , Meios de Cultura Livres de Soro/farmacologia , Olho , Fibroblastos/citologia , Órbita , Células-Tronco/citologia , Fosfatase Alcalina/genética , Linhagem da Célula/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Células Cultivadas , Fibroblastos/efeitos dos fármacos , Fibroblastos/enzimologia , Humanos , Células-Tronco/efeitos dos fármacos , Células-Tronco/enzimologia , Relação Estrutura-AtividadeRESUMO
Human adipose-derived stem cells (hASCs) are currently a point of focus for bone tissue engineering applications. However, the ex vivo expansion of stem cells before clinical application remains a challenge. Fetal bovine serum (FBS) is largely used as a medium supplement and exposes the recipient to infections and immunological reactions. In this study, we evaluated the osteogenic differentiation process of hASCs in poly-3-hydroxybutyrate-co-3-hydroxyvalerate (PHB-HV) scaffolds with the osteogenic medium supplemented with pooled allogeneic human serum (aHS). The hASCs grown in the presence of FBS or aHS did not show remarkable differences in morphology or immunophenotype. The PHB-HV scaffolds, which were developed by the freeze-drying technique, showed an adequate porous structure and mechanical performance as observed by micro-computed tomography, scanning electron microscopy (SEM), and compression test. The three-dimensional structure was suitable for allowing cell colonization, which was revealed by SEM micrographs. Moreover, these scaffolds were not toxic to cells as shown by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The differentiation capacity of hASCs seeded on scaffolds was confirmed by the reduction of the proliferation, the alkaline phosphatase (AP) activity, expression of osteogenic gene markers (AP, collagen type I, Runx2, and osteocalcin), and the expression of bone markers, such as osteopontin, osteocalcin, and collagen type I. The osteogenic capacity of hASCs seeded on PHB-HV scaffolds indicates that this scaffold is adequate for cell growth and differentiation and that aHS is a promising supplement for the in vitro expansion of hASCs. In conclusion, this strategy seems to be useful and safe for application in bone tissue engineering.
Assuntos
Adipócitos/citologia , Adipócitos/metabolismo , Osteoblastos/citologia , Osteogênese/fisiologia , Poliésteres/química , Soro/metabolismo , Alicerces Teciduais , Diferenciação Celular , Células Cultivadas , Desenho de Equipamento , Análise de Falha de Equipamento , Humanos , Osteoblastos/metabolismo , ProibitinasRESUMO
TEMA: a fenilcetonúria é uma doença genética que provoca alterações bioquímicas conduzindo a uma deficiência na síntese de proteínas e de neurotransmissores, e prejudicando o processo de mielinização. Mudanças estruturais e funcionais da mielina podem alterar os padrões de condutividade neuronal e ou diminuir a conexão sináptica em indivíduos com fenilcetonúria. Essencialmente, um tratamento dietético deve ser realizado dentro das primeiras semanas de vida para evitar as manifestações clínicas e bioquímicas da doença. Quando a dieta é mantida ininterruptamente, as crianças com fenilcetonúria apresentam desenvolvimento normal. Porém, foram observados déficits em funções executivas, na interação inter-hemisférica, na linguagem e memória mesmo em crianças com tratamento precoce e dieta adequada. Algumas pesquisas foram realizadas para investigação da relação entre fenilcetonúria e alterações auditivas. OBJETIVO: rever de forma sistemática os artigos científicos dedicados à pesquisa da relação entre alterações auditivas e hiperfenilalaninemias, destacando a fenilcetonúria clássica. As referências bibliográficas foram obtidas por meio de pesquisa nas bases de dados Lilacs, Medline, Biblioteca Cochrane e Scielo e por busca na lista de referência dos artigos identificados e selecionados. CONCLUSÃO: conclui-se que a relação entre hiperfenilalaninemias, incluindo a fenilcetonúria, e alterações auditivas ainda é controversa na literatura. Sugere-se a realização de mais investigações sobre a função auditiva nesses indivíduos a fim de elucidar essa possível relação.
BACKGROUND: phenylketonuria is a genetic disorder that causes biochemical alterations, leading to a deficiency in the synthesis of proteins and neurotransmitters and thereby hindering the myelination process. Structural and functional changes in myelin can alter neural conductivity patterns and or reduce synaptic connection in individuals with phenylketonuria. Essentially, a dietary treatment should be implemented in the first weeks of life in order to avoid clinical and biochemical manifestations of the disease. When diet is continually maintained, children with phenylketonuria show normal development. However, deficits in executive functions, interhemispherical interaction, language and memory have been observed even in children with early treatment and appropriate diet. Some researches were carried out for investigating the relationship between phenylketonuria and alterations in the hearing function. PURPOSE: to systematically review articles dedicated to the research of relationship between hearing disorders and hyperphenylalaninaemias, highlighting the classic phenylketonuria. The bibliographical references were obtained through research in the databases: Lilacs, Medline, Cochrane Library and Scielo and through search in the reference list of the identified and selected articles. CONCLUSION: the relationship among hyperphenylalaninaemias, including phenylketonuria, and hearing alterations is still controversial in the literature. It is suggested that more investigations as for the hearing function are necessary on those individuals in order to elucidate this possible relationship.